Jonas Grina

发表

Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process

Y. Ran, E. Choo, B. Alicke, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.

E. Laird, S. Gloor, G. Vigers, 2014, Bioorganic & medicinal chemistry letters.

The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.

Tyler T. Risom, E. Laird, S. Gloor, 2012, Bioorganic & medicinal chemistry letters.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.

E. Laird, Y. Ran, G. Hatzivassiliou, 2012, Journal of medicinal chemistry.

The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.

E. Laird, B. Brandhuber, G. Vigers, 2011, Bioorganic & medicinal chemistry letters.

Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.

J. Blake, Jianping Yin, Weiru Wang, 2015, Journal of medicinal chemistry.

Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

Tyler Risom, Zhaoyang Wen, Ignacio Aliagas, 2011, ACS medicinal chemistry letters.

Non-oxime pyrazole based inhibitors of B-Raf kinase.

E. Laird, B. Brandhuber, G. Vigers, 2011, Bioorganic & medicinal chemistry letters.

Potent and selective pyrazole-based inhibitors of B-Raf kinase.

Mike Welch, E. Laird, B. Brandhuber, 2008, Bioorganic & medicinal chemistry letters.

Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor.

Y. Ran, E. Choo, J. Boggs, 2013, International journal of pharmaceutics.

Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase.

Zhaoyang Wen, Joachim Rudolph, E. Laird, 2013, Bioorganic & medicinal chemistry letters.

Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.

Ellen R. Laird, Tyler Risom, Zhaoyang Wen, 2011, Bioorganic & medicinal chemistry letters.

Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.

E. Laird, S. Gloor, Jonas Grina, 2012, Bioorganic & medicinal chemistry letters.

Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development

S. Gould, M. Belvin, Peter Yin, 2014 .